Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

Europace

Volumn 17, Issue 10, 2015, Pages 1467-1507

  Heidbuchel, Hein ^a   Verhamme, Peter ^b   Alings, Marco ^c   Antz, Matthias ^d   Diener, Hans Christoph ^e   Hacke, Werner ^f   Oldgren, Jonas ^g   Sinnaeve, Peter ^b   Camm, A John ^h   Kirchhof, Paulus ^i,j  

^a HASSELT UNIVERSITY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c AMPHIA HOSPITAL   (Netherlands)

^d KLINIKUM OLDENBURG   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UPPSALA UNIVERSITY   (Sweden)

^h ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j UNIVERSITY OF MÜNSTER   (Germany)

more..

Author keywords

Anticoagulation; Atrial fibrillation; Bleeding; NOAC; Non VKA oral anticoagulants; Pharmacology; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTACID AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; CYTOCHROME P450 3A4 INHIBITOR; DABIGATRAN; DILTIAZEM; DRONEDARONE; EDOXABAN; GLYCOPROTEIN P INHIBITOR; NON VITAMIN K ANTAGONIST; OXIDOREDUCTASE INHIBITOR; RIVAROXABAN; UNCLASSIFIED DRUG; VERAPAMIL; ANTICOAGULANT AGENT;

ABLATION THERAPY; ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC IMPLANT; CARDIOVASCULAR RISK; CARDIOVERSION; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; DRUG OVERDOSE; DRUG SUBSTITUTION; FOLLOW UP; FOOD INTAKE; HEART ATRIUM THROMBOSIS; HOSPITAL MANAGEMENT; HUMAN; IMPLANTATION; LEFT ATRIAL APPENDAGE THROMBUS; MEDICATION COMPLIANCE; MULTIMODALITY CANCER THERAPY; NASOGASTRIC TUBE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NON VALVULAR ATRIAL FIBRILLATION; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE CORONARY ARTERY DISEASE; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; CLASSIFICATION; COMPLICATION; EUROPE; LANGUAGE; MEDICAL SOCIETY; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CORONARY ARTERY DISEASE; ELECTRIC COUNTERSHOCK; EUROPE; HEMORRHAGE; HUMANS; LANGUAGE; RENAL INSUFFICIENCY, CHRONIC; SOCIETIES, MEDICAL; STROKE;

EID: 84946208087     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv309     Document Type: Article

References (263)

1. Lip GY, Camm AJ, Hylek EM, Halperin JL, Weitz JI. Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. Chest 2014;145:1177-8.
2. Husted S, Lip GY, Disease ESCWGoTTFoAiH. Response to Ansell et al. Nonvitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014;112:842.
3. Barnes GD, AgenoW, Ansell J, Kaatz S, Subcommittee on the Control of A. Recommendation on the Nomenclature for Oral Anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:1154-6.
4. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12: 1360-420.
5. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation ∗ Developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
6. Heidbuchel H, Verhamme P, Alings M, Antz M, HackeW, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
7. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094-106.
8. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130: e199-267.
9. De Caterina R, Camm AJ. What is 'valvular' atrial fibrillation? A reappraisal. Eur Heart J 2014;35:3328-35.
10. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M et al. Apixaban in Compared with Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the ARISTOTLE Trial. Circulation 2015;132:624-32.
11. Ezekowitz MD, Parise H, Nagarakanti R, Noack H, Brueckmann M, Clemens A et al. Comparison of dabigatran versus warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LYw trial. J Am Coll Cardiol 2014;63(12, Supplement): A325.
12. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;35:3377-85.
13. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14.
14. The management of atrial fibrillation: NICE Guideline 180 (United Kingdom National Institute for Health and Care Excellence). https://www.nice.org.uk/guidance/cg180. June 2014.
15. Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA, Hills MT et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 2015;doi:10.1093/europace/euv233.
16. Heidbuchel H, Berti D, Campos M, Desteghe L, Freixo AP, Nunes AR et al. Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. Thromb J 2015;13:22.
17. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014;111:789-97.
18. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013;144:1555-63.
19. Ruiz-Ortiz M, Bertomeu V, Cequier A, Marin F, Anguita M. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015;114 [epub ahead of print].
20. Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, Lopez-Lopez A, Redondo-Dieguez A, Alvarez-Iglesias D et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace 2015;17:711-7.
21. Roldan V, Cancio S, Galvez J, Valdes M, Vicente V, Marin F et al. The SAMe-TTR score predicts poor anticoagulation control in AF patients: a prospective "Real-World" Inception Cohort Study. Am J Med 2015;doi: 10.1016/j.amjmed.2015.05.036.
22. Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014;146:719-26.
23. Proietti R, Lip GYH. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2score. Eur Heart J 2015;1:150-2.
24. Fauchier L, Angoulvant D, Lip GY. The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Europace 2015;17:671-3.
25. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139-51.
26. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-92.
27. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
28. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093-104.
29. Patel MR, MahaffeyKW, Garg J, Pan G, Singer DE, HackeWet al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
30. Lane DA, Wood K. Cardiology patient page. Patient guide for taking the nonvitamin K antagonist oral anticoagulants for atrial fibrillation. Circulation 2015; 131:e412-5.
31. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J 2012;33:2692-9.
32. Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ et al. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. Eur Heart J 2013;34:2725-30.
33. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-64.
34. Romero-Ortuno R, Walsh CD, Lawlor BA, Kenny RA. A frailty instrument for primary care: findings from the Survey of Health, Ageing and Retirement in Europe (SHARE). BMC Geriatr 2010;10:57.
35. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R et al. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 2009;11:860-85.
36. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50: 743-53.
37. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013;110:283-94.
38. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-41.
39. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
40. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-47.
41. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008;6:1542-9.
42. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogne JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012; 130:956-66.
43. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107:985-97.
44. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 2012;125:417-20.
45. PfeilschifterW, Abruscato M, Hovelmann S, Baas H. Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases. Case Rep Neurol 2013;5:56-61.
46. Bassiouny M, SalibaW, Rickard J, Shao M, Sey A, DiabMet al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013;6:460-6.
47. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010;32:673-9.
48. MueckW, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50:675-86.
49. Mani H, Herth N, Kasper A, Schüttfort G, Weil Y, Linnemann B et al. Influence of rivaroxaban on point-of-care devices. https://www.dgim-onlinekongress.de/fileadmin/dgim2013/postervortraege/which-assay-may-be-useful-for-monitoringrivaroxaban- in-emergency-situations.pdf (7 April 2013, date last accessed).
50. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V et al. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol 2015;115:47-51.
51. Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Absolute Bioavailability of Edoxaban in Healthy Subjects. The AAPS Journal 2011;13(Suppl):S2. (abstract).
52. Raghavan N, Frost CE, Yu Z, He K, Zhang H, HumphreysWGet al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81.
53. Frost C, Yu Z, Nepal S, Bragat A, Moore K, Shenker A et al. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 2008;48:1132 (abstract).
54. Vakkalagadda B, Frost C, Wang J, Nepal S, Schuster A, Zhang D et al. Effect of rifampicin on the pharmacokinetics of apixaban, on oral direct inhibitor of factor Xa. J Clin Pharmacol 2009;49:1124 (abstract).
55. Frost C, Boyd RA. The contribution of apixaban renal clearance to total clearance. J Thromb Thrombolysis 2015;doi: 10.1007/s11239-015-1220-8.
56. Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacol Drug Dev 2013;2:358-66.
57. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010;38: 448-58.
58. Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 2011;51:687-94.
59. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-58.
60. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, RothW. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99.
61. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59.
62. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9:2168-75.
63. Upreti VV, Song Y, Wang J, ByonW, Boyd RA, Pursley JM et al. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol 2013;5:59-66.
64. Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol 2011;58:581-8.
65. Mendell J, Chen S, He L, Desai MY, Parasrampuria D. The effect of rifampin on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban in healthy subjects. Thromb Haemost 2014;12(Suppl 1):17.
66. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011;338:372-80.
67. MueckW, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013;76:455-66.
68. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J 2015; doi:10.1093/eurheartj/ehv201.
69. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012;107:925-36.
70. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013;13:331-42.
71. Stangier J, Stahle H, Rathgen K, RothW, Reseski K, Kornicke T. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol 2012;52:243-50.
72. Kubitza D, Becka M, Zuehlsdorf M, MueckW. No interaction between the novel, oral direct factor Xa inhibitor BAY 59-7939 and digoxin. J Clin Pharmacol 2006;46: 702 (Abstract 11).
73. MueckW, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013;76:455-66.
74. Frost CE, ByonW, Song Y, Wang J, Schuster AE, Boyd RA et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 2015;79:838-46.
75. Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, Ebner T, Schaefer O. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold. Drug Metab Dispos 2014;42:257-63.
76. Mendell J, Noveck R, Zahir H, Lee F, Petrushin V, Rubets I et al. The effect of quinidine and verapamil, P glycoprotein/CYP3A4/5 inhibitors, on edoxaban pharmacokinetics and pharmacodynamics. Basic Clin Pharmacol Toxicol 2010;107:2848. (Abstract).
77. Matsushima N, Mendell J, Zahir H. Effects of quinidine on pharmacokinetics (PK) of oral (PO) and intravenously (IV) administered edoxaban. Clin Pharmacol Ther 2011;91(Suppl 1):P-72 (abstract).
78. Stangier J, Rathgen K, Stahle H, Reseski K, Kornicke T, RothW. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009;9:59-68.
79. Kubitza D, Becka M, Roth A, MueckW. Absence of clinically relevant interactions between rivaroxaban-an oral, direct Factor Xa inhibitor-and digoxin or atorvastatin in healthy subjects. J Int Med Res 2012;40:1688-707.
80. Hartter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, TimmerWet al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 2012;74:490-500.
81. Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol 2014;78:877-85.
82. Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol 2014;64:1541-50.
83. Steinberg BA, Hellkamp AS, Lokhnygina Y, Halperin JL, Breithardt G, Passman R et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm 2014;11:925-32.
84. LaHaye SA, Gibbens SL, Ball DG, Day AG, Olesen JB, Skanes AC. A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. Eur Heart J 2012;33:2163-71.
85. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94.
86. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63:321-8.
87. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AFTIMI 48 trial. Lancet 2015;385:2288-95.
88. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014;111:933-42.
89. Song Y, Chang M, Frost R, Kelly A, LaCreta F, Frost C. Relative bioavailability of crushed apixaban tablets administered with water or applesauce in healthy subjects. Clin Pharmacol Ther 2013;97(supplement 1):S42.
90. Song Y, Wang X, Perlstein I, Wang J, Badawy SI, Pursley J et al. Bioavailability of apixaban solution formulation and crushed tablet via nasogastric tube. Clin Pharmacol Ther 2013;93(supplement 1):S120-1.
91. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127:634-40.
92. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
93. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365: 699-708.
94. Ruff CT, Giugliano RP, Braunwald E, Mercuri M, Curt V, Betcher J et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2014;64:576-84.
95. FDA Advisory Committee Briefing Document 27 August 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270796.pdf (27 August 2010, date last accessed).
96. Granger C, Alexander JH, Hanna M, Wang J, Mohan P, Lawrence J et al. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. Eur Heart J 2012;33(Suppl):685-6. (abstract).
97. Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2015;169:25-30.
98. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012;52:275-301.
99. Laliberte F, NelsonWW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-90.
100. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61: 2264-73.
101. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015;13:495-504.
102. Cutler TW, Chuang A, Huynh TD, Witt RG, Branch J, Pon T et al. A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center. J Manag Care Spec Pharm 2014;20:1028-34.
103. Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2015;114 [epub ahead of print].
104. Beyer-Westendorf J, Forster K, Ebertz F, Gelbricht V, Schreier T, Gobelt M et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015;17:530-8.
105. Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F, Kohler C et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015;113: 1247-57.
106. Pan X, Kachroo S, Liu X, Kawabata H, Phatak H. Discontinuation among early users of apixaban, dabigatran, rivaroxaban or warfarin among atrial fibrillation patients newly initiated on anticoagulation therapy: tale of first 200 days. Eur Heart J 2014;35(Abstract Supplement):897.
107. Lane DA, Barker RV, Lip GY. Best practice for atrial fibrillation patient education. Curr Pharm Des 2015;21:533-43.
108. Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AJ, McCollam PL et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 2012;18:139-46.
109. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23.
110. Olesen JB, Lip GYH, Kamper A-L, Hommel K, Kober L, Lane DA et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367: 625-35.
111. Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015;17:1169-96.
112. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33:2821-30.
113. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014;129: 961-70.
114. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014;64:2471-82.
115. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts. Circulation 2013;127:224-32.
116. Camm AJ, Savelieva I. "R" for "renal" and for "risk": refining risk stratification for stroke in atrial fibrillation. Circulation 2013;127:169-71.
117. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011;6: 2599-604.
118. Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB. Renal function and nonvitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol 2015;104:418-29.
119. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011;6:2662-8.
120. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015;131: 972-9.
121. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011;57:1339-48.
122. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an openlabel, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68.
123. Chang M, Shenker A, Wang J, Yu Z, Pursley J, Boyd R et al. Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment. Clin Pharmacol Drug Dev 2012;1:185.
124. Ridout G, de la Motte S, Niemczyk S, Sramek P, Johnson L, Jin J et al. Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PK-PD model. J Clin Pharmacol 2009;49:1124. (abstract).
125. Kubitza D, Becka M, MueckW, Halabi A, Maatouk H, Klause N et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010;70:703-12.
126. MueckW, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014;53:1-16.
127. De Vriese AS, Caluwe R, Bailleul E, De Bacquer D, Borrey D, Van Vlem B et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015;66:91-8.
128. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72.
129. Kooiman J, Van Der Hulle T, Maas H, Pichereau S, Formella S, Clemens A et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate 75 mg BID in patients with severe chronic kidney disease: prospective validation of a post hoc determined dose. Eur Heart J 2014;35(Abstract Suppl):428.
130. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-65.
131. Green R, Grierson R, Sitar DS, Tenenbein M. How long after drug ingestion is activated charcoal still effective? J Toxicol Clin Toxicol 2001;39:601-5.
132. Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014;14:147-54.
133. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014;63:2141-7.
134. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013;128:2325-32.
135. Hanley JP. Warfarin reversal. J Clin Pathol 2004;57:1132-9.
136. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955-62.
137. Honickel M, Treutler S, van Ryn J, Tillmann S, Rossaint R, Grottke O. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 2015;113:728-40.
138. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-20.
139. Lauw MN, Coppens M, Eikelboom JW. Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent. Can J Cardiol 2014;30:381-4.
140. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371:2141-2.
141. Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the nonvitamin K oral anticoagulants. Europace 2015;doi:10.1093/europace/euv030.
142. Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, doubleblind phase 1 trial. Lancet 2015;386:680-90.
143. Glund S, Stangier J, Schmohl M, Moschetti V, Haazen W, De Smet M et al. Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. Blood 2014;124:344.
144. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011;9: 1705-12.
145. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012;119:2172-4.
146. Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012;46:e21.
147. Getta B, Muller N, Motum P, Hsu D, Zebeljan D, Rosenfeld D. Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran. Br J Haematol 2015;169:603-4.
148. Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost 2015;113:719-27.
149. Wang X, Tirucherai G, Ehlgen A, Wang J, Chang M, Zhang D et al. Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis. Clin Pharmacol Drug Dev 2012;1:187.
150. ZhouW, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011;42:3594-9.
151. Pragst I, Dörr B, Kaspereit F, KregeW, Zeitler SH, van Ryn J. Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits. Pathophysiol Haemost Thromb 2010;37(Suppl 1):A94.
152. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012;10:1841-8.
153. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012;116:94-102.
154. Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015;131:82-90.
155. Eerenberg ES, KamphuisenPW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573-9.
156. Perlstein I, Wang Z, Song Y, Wang J, Bedford B, Chang M et al. Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects. Blood 2014;124:345.
157. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108:217-24.
158. Escolar G, Arellano-Rodrigo E, Reverter JC, Villalta J, Sanz V, Molina P et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. AHA Emerging Science Series, June 20, 2012. Circulation 2012;126:520-1 (Abstract).
159. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, Sanz VV et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS ONE 2013;8:e78696.
160. van Ryn J, Ruehl D, Priepke H, Hauel N, WienenW. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica 2008;93(Suppl 1):148.
161. Dentali F, Marchesi C, Giorgi Pierfranceschi M, Crowther M, Garcia D, Hylek E et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011;106:429-38.
162. Baudo F, Collins P, Huth-Kuhne A, Levesque H, Marco P, Nemes L et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012;120:39-46.
163. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012;126:343-8.
164. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014;35:1888-96.
165. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;doi: 10.1056/NEJMoa1501035.
166. Sie P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the working group on perioperative haemostasis and the french study group on thrombosis and haemostasis. Arch Cardiovasc Dis 2011;104:669-76.
167. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace 2015;17:1197-214.
168. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003;123:676-82.
169. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:32-8.
170. Bun SS, Latcu DG, Saoudi N. Should catheter atrial fibrillation ablation be considered as a 'high bleeding risk' intervention? Europace 2014;16:150-1.
171. Heidbuchel H, Verhamme P, Alings M, Antz M, HackeW, Oldgren J et al. Author reply: to "Should catheter atrial fibrillation ablation be considered as a 'high bleeding risk' intervention?" Europace 2014;16:151-2.
172. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. EP Europace 2012;14:528-606.
173. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial. Circulation 2014;129:2638-44.
174. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013; 15:1407-11.
175. Providencia R, Albenque JP, Combes S, Bouzeman A, Casteigt B, Combes N et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014; 100:324-35.
176. Shurrab M, Morillo CA, Schulman S, Kansal N, Danon A, Newman D et al. Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Can J Cardiol 2013; 29:1203-10.
177. Sardar P, Nairooz R, Chatterjee S, Wetterslev J, Ghosh J, Aronow WS. Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol 2014;113:1173-7.
178. Bin Abdulhak AA, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwalt KE et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace 2013;15:1412-20.
179. Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR et al. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2014;114:577-82.
180. Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H et al. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Pacing Clin Electrophysiol 2015;38:155-63.
181. Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study. Heart Rhythm 2015;12:1162-8.
182. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2014;63:982-8.
183. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805-11.
184. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368:2084-93.
185. Rowley CP, Bernard ML, Brabham WW, Netzler PC, Sidney DS, Cuoco F et al. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol 2013;111:1165-8.
186. Jennings JM, Robichaux R, McElderry HT, Plumb VJ, Gunter A, Doppalapudi H et al. Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin. J Cardiovasc Electrophysiol 2013;24:1125-9.
187. Kosiuk J, Koutalas E, Doering M, Sommer P, Rolf S, Breithardt OA et al. Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. Europace 2014;16:1028-32.
188. Kate M, Szkotak A, Witt A, Shuaib A, Butcher K. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. J Stroke Cerebrovasc Dis 2014;23:1351-5.
189. Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH et al. Shortand long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart 2008;94:867-73.
190. Rubboli A, Schlitt A, Kiviniemi T, Biancari F, Karjalainen PP, Valencia J et al. Oneyear outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Clin Cardiol 2014;37:357-64.
191. Rene AG, Genereux P, Ezekowitz M, Kirtane AJ, Xu K, Mehran R et al. Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). Am J Cardiol 2014;113:236-42.
192. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-619.
193. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of CardiologyWorking Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart RhythmSociety (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35:3155-79.
194. Gorenek B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, Huber K et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace 2014;16:1655-73.
195. Potpara TS, Lip GY, Dagres N, Estner HL, Larsen TB, Blomstrom-Lundqvist C, et al. Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace 2014;16:293-8.
196. Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 2009;30:2019-28.
197. Lopes RD, Starr A, Pieper CF, Al-Khatib SM, Newby LK, Mehta RH et al.Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med 2010;123:134-40.
198. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR.Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-50.
199. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H.Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
200. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002;105:557-63.
201. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. J Am Coll Cardiol 2001;37:475-84.
202. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet 1997;350:389-96.
203. Lip GY. Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ 2008;336:614-5.
204. Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014;129:1577-85.
205. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374:1967-74.
206. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012;126:1185-93.
207. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-15.
208. Fiedler KA, Byrne RA, Schulz S, Sibbing D, Mehilli J, Ibrahim T et al. Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. Am Heart J 2014;167:459-65 e1.
209. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol 2015;65:1619-29.
210. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-9.
211. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, StegGet al. Neworal anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013;34:1670-80.
212. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
213. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
214. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-66.
215. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372:1791-800.
216. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397-402.
217. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125:669-76.
218. US Food and Drug Administration DSC. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm (13 May 2014, date last accessed).
219. Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15.
220. Karjalainen PP, Vikman S, Niemela M, Porela P, Ylitalo A, Vaittinen MA et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008;29:1001-10.
221. Vranckx P, Verheugt FW, de Maat MP, Ulmans VA, Regar E, Smits P et al. A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. EuroIntervention 2013;8:1052-60.
222. Vranckx P, Leebeek FW, Tijssen J, Koolen J, Stammen F, Herman JP et al. Periprocedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial. Thromb Haemost 2015;114:258-67.
223. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218-30.
224. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58.
225. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797-804.
226. Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007;50:1742-51.
227. Faber L, Seggewiss H, Fassbender D, Bogunovic N, Strick S, Schmidt HK et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography. Z Kardiol 1998;87:191-201.
228. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
229. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355: 2203-16.
230. Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2014;35:224-32.
231. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012;59:1413-25.
232. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van deWerf F et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). Br Med J 2006;333:1091.
233. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.
234. Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol 2013;62:286-90.
235. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
236. Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace 2015; 17:18-23.
237. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-6.
238. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014;63:1082-7.
239. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013;61: 1998-2006.
240. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;35:3346-55.
241. McCready JW, Nunn L, Lambiase PD, Ahsan SY, Segal OR, Rowland E et al. Incidence of left atrial thrombus prior to atrial fibrillation ablation: is pre-procedural transoesophageal echocardiography mandatory? Europace 2010;12:927-32.
242. Puwanant S, Varr BC, Shrestha K, Hussain SK, Tang WH, Gabriel RS et al. Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol 2009;54:2032-9.
243. Scherr D, Dalal D, Chilukuri K, Dong J, Spragg D, Henrikson CA et al. Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2009;20:379-84.
244. Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B et al. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J 2015;169:464-71 e2.
245. Radberg JA, Olsson JE, Radberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke 1991;22:571-6.
246. Bronnum Nielsen P, Larsen TB, Gorst-Rasmussen A, Skjoth F, Rasmussen LH, Lip GY. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. Chest 2015;147:1651-8.
247. Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting anticoagulant treatment after intracranial haemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality and bleeding: a Nationwide Cohort Study. Circulation 2015;132:517-25.
248. Morgenstern LB, Hemphill JC 3rd, Anderson C, Becker K, Broderick JP, Connolly ES Jr et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010;41:2108-29.
249. Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, Csiba L et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 2014;9:840-55.
250. Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep 2014;16:480.
251. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012;43:1511-7.
252. HackeW. Interventional thrombectomy for major stroke-a step in the right direction. N Engl J Med 2015;372:76-7.
253. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296-306.
254. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015; 372:2285-95.
255. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015;313:824-36.
256. Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2014;85:660-7.
257. Horstmann S, Zugck C, Krumsdorf U, Rizos T, Rauch G, Geis N et al. Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage. Neurology 2014;82:135-8.
258. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999;353:2179-84.
259. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21.
260. Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015;114:150-7.
261. VersoM, Agnelli G, Prandoni P. Pros and cons of neworal anticoagulants in the treatment of venous thromboembolism in patients with cancer. Intern Emerg Med 2015 [epub ahead of print].
262. Larsen TB, Nielsen PB, Skjoth F, Rasmussen LH, Lip GY. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS ONE 2014;9:e114445.
263. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500-10.